trending Market Intelligence /marketintelligence/en/news-insights/trending/dgq3knmDDZGkWeU3sZsK7Q2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Avadel Pharmaceuticals to lay off 50 employees in France

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Avadel Pharmaceuticals to lay off 50 employees in France

Avadel Pharmaceuticals plc plans to reduce its headcount in France by about 50 people.

The company said the reduction will help align the its cost structure with ongoing and planned projects, but will not affect allocation of resources to its REST-ON phase 3 clinical trial or other important pipeline initiatives.

Avadel expects the reduction, which is subject to regulatory requirements, to be substantially completed by end of July. The company expects to incur severance, benefits and other costs of about $2.5 million to $4 million, and anticipates annual cost savings of about $3.5 million to $4.0 million once the plan is implemented.

The REST-ON trial is meant to assess the efficacy and safety of a once-nightly formulation of sodium oxybate for extended-release oral suspension to treat excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy.